Moleculin Biotech (NASDAQ:MBRX) Coverage Initiated by Analysts at StockNews.com
StockNews.com began coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a research note issued to investors on Monday morning. The firm issued a sell rating on the stock. Separately, Maxim Group lowered Moleculin Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, February 12th. Get Our […]
StockNews.com began coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a research note issued to investors on Monday morning. The firm issued a sell rating on the stock. Separately, Maxim Group lowered Moleculin Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, February 12th. Get Our […]
